rs3818416
Variant names:
Your query was ambiguous. Multiple possible variants found:
Variant summary
Our verdict is Benign. The variant received -14 ACMG points: 0P and 14B. BP4_StrongBP6_ModerateBA1
The NM_001122659.3(EDNRB):c.1085+188T>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.749 in 151,704 control chromosomes in the GnomAD database, including 42,780 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★).
Frequency
Genomes: 𝑓 0.75 ( 42780 hom., cov: 31)
Consequence
EDNRB
NM_001122659.3 intron
NM_001122659.3 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: -0.350
Publications
25 publications found
Genes affected
EDNRB (HGNC:3180): (endothelin receptor type B) The protein encoded by this gene is a G protein-coupled receptor which activates a phosphatidylinositol-calcium second messenger system. Its ligand, endothelin, consists of a family of three potent vasoactive peptides: ET1, ET2, and ET3. Studies suggest that the multigenic disorder, Hirschsprung disease type 2, is due to mutations in the endothelin receptor type B gene. Alternative splicing and the use of alternative promoters results in multiple transcript variants. [provided by RefSeq, Oct 2016]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -14 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.86).
BP6
Variant 13-77900333-A-C is Benign according to our data. Variant chr13-77900333-A-C is described in ClinVar as Benign. ClinVar VariationId is 1246466.Status of the report is criteria_provided_single_submitter, 1 stars.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.863 is higher than 0.05.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.749 AC: 113514AN: 151586Hom.: 42767 Cov.: 31 show subpopulations
GnomAD3 genomes
AF:
AC:
113514
AN:
151586
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.749 AC: 113569AN: 151704Hom.: 42780 Cov.: 31 AF XY: 0.751 AC XY: 55626AN XY: 74116 show subpopulations
GnomAD4 genome
AF:
AC:
113569
AN:
151704
Hom.:
Cov.:
31
AF XY:
AC XY:
55626
AN XY:
74116
show subpopulations
African (AFR)
AF:
AC:
28118
AN:
41406
American (AMR)
AF:
AC:
12271
AN:
15202
Ashkenazi Jewish (ASJ)
AF:
AC:
2193
AN:
3460
East Asian (EAS)
AF:
AC:
4519
AN:
5108
South Asian (SAS)
AF:
AC:
3760
AN:
4804
European-Finnish (FIN)
AF:
AC:
8173
AN:
10562
Middle Eastern (MID)
AF:
AC:
203
AN:
294
European-Non Finnish (NFE)
AF:
AC:
52142
AN:
67856
Other (OTH)
AF:
AC:
1537
AN:
2102
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.505
Heterozygous variant carriers
0
1429
2857
4286
5714
7143
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
852
1704
2556
3408
4260
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
2760
AN:
3478
ClinVar
Significance: Benign
Submissions summary: Benign:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not provided Benign:1
Nov 11, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.